Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report

PURPOSE: HER2 mutations are identified in approximately 2% of non-small-cell lung cancer (NSCLC) cases; however, until now, there are no approved standard targeted therapy for NSCLC patients harboring HER2 mutations. CASE PRESENTATION: We present a 63-year-old male with a long smoking history, who w...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Ling, Ge, Hongfei, Yan, Zhengqing, Wang, Guoqiang, Wu, Xiaomai, Lv, Dongqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913761/
https://www.ncbi.nlm.nih.gov/pubmed/31849493
http://dx.doi.org/10.2147/OTT.S228726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913761/
https://www.ncbi.nlm.nih.gov/pubmed/31849493
http://dx.doi.org/10.2147/OTT.S228726

Ejemplares similares